Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Bryan Cearley

Physician Assistant Little Rock, AR Physician Assistant

NPI 1023597655 CMS profile 10676051

10001 Lile Dr, Little Rock, AR 72205

Open in the dashboard

General payments

$4,914

193 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Bryan Cearley of Little Rock, AR is reported in the CMS Open Payments database as having received $4,914 across 193 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 91st percentile of Physician Assistant profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $44 2
2024 General $1,087 47
2023 General $2,395 73
2022 General $577 31
2021 General $811 40

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Bryan Cearley
  • Physician Assistant median
  • Middle half of Physician Assistant
  • National median

In program year 2025, general payments to Bryan Cearley were reported at $44. Among 68,903 Physician Assistant profiles paid that year, the median was $184 and the middle half received between $57 and $620.

Show as a table
Year Bryan Cearley Physician Assistant median Middle half National median
2019 $0 $34 $17–$122 $163
2020 $0 $33 $16–$78 $114
2021 $811 $132 $37–$438 $132
2022 $577 $155 $48–$522 $149
2023 $2,395 $167 $52–$557 $160
2024 $1,087 $178 $55–$600 $164
2025 $44 $184 $57–$620 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Teleflex LLC $658 9 payments
  2. Myriad Genetic Laboratories, Inc. $550 7 payments
  3. Sumitomo Pharma America, Inc. $549 37 payments
  4. Astellas Pharma US Inc $482 21 payments
  5. Dendreon Pharmaceuticals LLC $423 18 payments
  6. AbbVie, Inc. $286 14 payments
  7. Endo Pharmaceuticals Inc. $280 7 payments
  8. Janssen Biotech, Inc. $250 13 payments
  9. Rochester Medical Corporation $215 12 payments
  10. Blue Earth Diagnostics Limited $174 9 payments
  11. Other $1,048 46 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $4,179 186 payments
  2. Travel and Lodging $461 3 payments
  3. Education $274 4 payments
Products named General payments · program years 2021–2025
  1. UROLIFT $658 9 payments
  2. myRisk $521 5 payments
  3. PROVENGE $423 18 payments
  4. GEMTESA $362 29 payments
  5. XTANDI $310 15 payments
  6. XIAFLEX $299 8 payments
  7. ORGOVYX $230 11 payments
  8. ERLEADA $203 10 payments
  9. XYOSTED $183 9 payments
  10. JELMYTO $153 3 payments
  11. Other $1,610 83 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 29 drugs

Part D claims

2,447

Median for Physician Assistant: 241

Drug cost

$1,084,643

Median for Physician Assistant: $4,110

Branded share of claims

24.2%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Xtandi Enzalutamide Brand 61 $866,855
Gemtesa Vibegron Brand 134 $78,076
Myrbetriq Mirabegron Brand 117 $65,100
Xyosted Testosterone Enanthate Brand 17 $16,677
Testosterone Cypionate Generic 277 $11,707
Tamsulosin Hcl Generic 755 $11,326
Finasteride Generic 384 $4,718
Solifenacin Succinate Generic 114 $4,329
Testosterone Generic 25 $3,209
Methenamine Hippurate Generic 40 $3,005

The 10 drugs with the highest cost, of 29 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 115 billing codes

Paid by Medicare

$434,670

Of which drugs: $183,027

Medicare patients

1,233

Average age 75

Services billed

37,049

208 women, 1,025 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 48%
Ischemic heart disease 44%
Diabetes 36%
Cancer 34%
Atrial fibrillation 24%
Chronic kidney disease 23%
Heart failure 19%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, denosumab, 1 mg J0897 Office 39 6,420 $129,767
Leuprolide acetate (for depot suspension), 7.5 mg J9217 Office 43 276 $39,001
Bcg live intravesical instillation, 1 mg J9030 Office 12 1,075 $2,429

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 15 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
ORGOVYX
  • Sumitomo Pharma America, Inc. $118
  • PFIZER INC. $16
$135 — —
JELMYTO
  • UROGEN PHARMA, INC. $128
$128 — —
XTANDI
  • Astellas Pharma US Inc $71
  • PFIZER INC. $56
$127 61 —
PROVENGE
  • Dendreon Pharmaceuticals LLC $126
$126 — —
GEMTESA
  • Sumitomo Pharma America, Inc. $91
$91 134 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 15 in the dashboard with a free account

Records

193 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant in Arkansas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record